Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery

Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.

Telix Pharmaceuticals is pleased to announce it has entered into an exclusive Intellectual Property (IP) licence agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum or ‘DKFZ’) for a novel imaging technology in the field of image-guided surgery for prostate cancer.

The licence agreement is the result of Telix exercising its option under a research collaboration agreement entered into with the DKFZ in August 2019.

This innovative technology involves the use of a ‘dual-labelled’ prostate-specific membrane antigen (PSMA)-targeting molecule that comprises both a radioactive isotope (68Ga) and a fluorescent dye. The resulting imaging agent is able to simultaneously provide both pre-operative imaging of prostate cancer patients with Positron Emission Tomography (PET), as well as highly accurate intra-operative visual (fluorescent) localisation of prostate cancer tissue in real-time by the surgeon.

Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated “Robotic surgery delivers over seven million procedures a year globally and already makes extensive use of intra-operative fluorescent imaging. Bringing molecular imaging into the operating theatre is a natural evolution of Telix’s existing commitment to prostate cancer imaging. Our colleagues at the DKFZ have been acknowledged as world leaders in the field of prostate cancer imaging and we are delighted to be further expanding our prostate cancer imaging capability with this excellent technology.”

To read the full ASX release please click here.

TLX591-CDx does not have regulatory approval in any jurisdiction.